and may be good candidates for vaccine development. In this study, we examined immunity induced by rMuV⌬SH and rMuV⌬V in mice. Furthermore, we generated recombinant mumps viruses lacking expression of both the V protein and the SH protein (rMuV⌬SH⌬V). Analysis of rMuV⌬SH⌬V indicated that it was stable in tissue culture cell lines. Importantly, rMuV⌬SH⌬V was immunogenic in mice, indicating that it is a promising candidate for mumps vaccine development.
M
umps is a human infectious disease characterized by lateral or bilateral nonsuppurative swelling of the parotid glands. In severe cases, mumps can lead to orchitis in postpuberty male patients and damage to the central nervous system. In the prevaccine era, 90% of the population turned seropositive for mumps virus (MuV) by 14 to 15 years of age, reflecting its highly contagious nature. Mumps virus is neurotropic and was one of the most common causes of aseptic meningitis before the implementation of mass mumps vaccination programs.
At present, the Jeryl Lynn (JL) vaccine is the most commonly used mumps vaccine, administered as lyophilized live virus with measles and rubella vaccine components. The JL vaccine strain originated from an infectious isolate from a mumps patient in 1963 (1) . The virus was attenuated through continuous passages in embryonic hen eggs and chicken embryos/chicken embryo cell cultures (1) . The JL vaccine was licensed in the United States in 1967 and has been used for over 40 years. This vaccine has been efficacious and safe overall (2-6). However, several large mumps outbreaks have occurred recently in the United States and worldwide in populations that have been vaccinated with the JL vaccine (7) (8) (9) (10) . Major mumps outbreaks in the United States include the 2006 multistate mumps outbreak, reporting 6,584 suspected cases originating from the state of Iowa (11, 12) and the 2009 -2010 New York and New Jersey mumps outbreaks with a total of 2,078 suspected cases reported in 2010 (13) . Both of the outbreaks occurred among highly vaccinated populations, raising questions about the efficacy of the current vaccination program in the United States. One possible causality is the antigenic differences between the genotype A vaccine strain and the genotype G circulating wild-type mumps viruses.
In this study, we seek to develop a mumps vaccine candidate through genetic modification of a clinically isolated mumps virus. Mumps virus is a member of the family Paramyxoviridae, subfamily Paramyxovirinae, and genus Rubulavirus (6, 14) . It is an enveloped virus enclosing a negative-sense, single-stranded, nonsegmented RNA genome of 15,384 nucleotides in length which encodes 9 viral proteins (15) (16) (17) . Studies of the function of the Paramyxovirus SH protein reveal that it blocks tumor necrosis factor alpha (TNF-␣) induction, signaling, caspase activation, and NF-B nuclear translocation in transfected and virus-infected cells (18) (19) (20) (21) (22) (23) . The V protein is an accessory protein translated from the authentic transcript of the V/P gene (24, 25) . Mumps V protein is an antagonist of antiviral innate immunity. It interferes with type I interferon (IFN) induction by disrupting the recognition of intracellular viral double-stranded RNA (dsRNA) by MDA5 (26) (27) (28) . It also blocks IFN signaling by targeting STAT proteins for proteasome-mediated degradation (29) (30) (31) (32) (33) (34) (35) . Recombinant mumps viruses with either the V protein deletion (rMuV⌬V) or the SH protein deletion (rMuV⌬SH) are attenuated in neurotoxicity in intracerebrally (IC) infected rats (21, 36) .
In this study, we tested the immunogenicity of rMuV⌬V and rMuV⌬SH in mice. Furthermore, we generated a recombinant MuV lacking expression of both the SH and V proteins (rMuV⌬SH⌬V) and examined antibody and cellular immune responses in mice.
MATERIALS AND METHODS
Plasmids, viruses, and cells. The MuV strain was obtained from a patient during the 2005-2006 Midwest mumps outbreak in the United States. A full-length cDNA clone of the virus (pMuV) was constructed as previously described (21) . Recombinant MuV lacking the V protein (rMuV⌬V), recombinant MuV lacking the SH protein, and recombinant MuV expressing a Renilla luciferase protein have been described before (21) . A plasmid containing the MuV genome but lacking both V and SH was constructed by combining the SH open reading frame (ORF) deletion with the plasmid encoding the rMuV⌬V genome. Primer sequences, detailed cloning strategies, and entire cDNA sequences of MuV are available upon request. Jeryl Lynn (JL) vaccine, isolated from the measles, mumps, and rubella (MMR) vaccine, was a gift from Paul Rota at the CDC.
To rescue an infectious virus, plasmid pMuV⌬SH⌬V (5 g), along with plasmids pCAGGS-L (1 g), pCAGGS-NP (1.5 g), and pCAGGS-P (200 ng), were transfected into BSRT-7 cells. Three days later, transfected BSRT-7 cells were mixed with Vero cells at a 1:1 ratio. Ten to 14 days later, when syncytium formation was observed, supernatants containing putative rMuV⌬SH⌬V were collected and plaque purified in Vero cells. Plaques (developing 4 to 7 days postinfection [dpi]) were amplified in Vero cells once (P 0 ), and their genomes were sequenced. All recombinant viruses used for the following experiments were expanded once in Vero cells from the P 0 amplification (P 1 ). The rescue procedure was repeated to produce independent stocks of rMuV⌬SH⌬V, resulting in 6 isolates of independently rescued rMuV⌬SH⌬V viruses (PX64-1, PX64-4, PX64-61, PX64-67, and PX64-84).
All mumps viruses were grown in Vero cells and harvested at 4 to 7 dpi. Virus titers were measured in Vero cells by plaque assay as described previously (37, 38) . JL virus was grown in Vero cells and concentrated to achieve a working titer. Harvested virus stock was cushioned onto 20% sucrose using ultracentrifugation at 37,500 rpm (Thermo Scientific Sorvall RC 6 plus centrifuge). Pelleted viruses were resuspended in 1% bovine serum albumin (BSA)-Dulbecco's modified Eagle medium (DMEM) and stored at Ϫ80°C. Concentrated JL virus was retitrated in Vero cells by plaque assay.
Vero cells were maintained in DMEM with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) (Mediatech Inc., Holu Hill, FL). BSRT-7 cells were maintained in DMEM supplemented with 10% FBS, 1% P/S, 10% tryptose phosphate broth (TPB), and 400 g/ml Geneticin G418 antibiotic. Cells were cultured at 37°C with 5% CO 2 and passed the day before infection or transfection at appropriate dilution factors to achieve 80 to 90% confluence the next day. For virus infection, cells were inoculated with viruses in DMEM plus 1% BSA at an multiplicity of infection (MOI) of 0.01, 3, or 5 and incubated for 1 to 2 h at 37°C with 5% CO 2 . The inocula were then replaced with DMEM supplemented with 2% FBS and 1% P/S. Cells were transfected with plasmids using Plus and Lipofectamine reagents (Invitrogen, Carlsbad, CA) by following the manufacturer-provided protocols.
Sequencing of viruses. Viral RNA was extracted from cell culture supernatants using the QIAamp viral RNA extraction minikit (Qiagen Inc., Valencia, CA) by following the manufacturer's protocol. Isolated viral RNA was reverse transcribed into cDNA using Super Script III reverse transcriptase with random hexamers (Invitrogen). Synthesized cDNA then served as templates for PCR using mumps virus genome-specific primers and Taq polymerase (Invitrogen). Fifteen sets of primers, each containing a forward and reverse primer, were designed to divide the genome into 15 overlapping fragments. The primers were then used for the subsequent sequencing of the PCR products (39) . Primer sequences are available upon request.
Immunoblotting. Vero cells in 6-well plates at approximately 90% confluence were mock infected or infected with rMuV or rMuV⌬SH⌬V at an MOI of 0.5. Cells were lysed and collected at different time points postinfection in 0.5 ml WCEB buffer (50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 0.5% NP-40, 0.00076% EGTA, 0.2 mM EDTA, 10% glycerol) with a mixture of protease inhibitors as described previously (30, 31) . Cell lysates were briefly centrifuged to remove cell debris and loaded onto a 10% or 17.5% polyacrylamide gel and subjected to SDS-PAGE. Proteins were transferred to an Immobilon-FL transfer membrane (Millipore, Billerica, MA), incubated with primary antibody (anti-MuV V, 1:500; antiMuV NP, 1:5,000; anti-MuV P, 1:2,000; and anti-MuV SH, 1:200) (21) and corresponding secondary antibodies conjugated to horseradish peroxidase (1:1,000) (KPL, Inc.) and detected using an Amersham ECL Western blotting detection kit (GE Healthcare Bioscience, Piscataway, NJ).
Multicycle growth curve in Vero cells. Vero cells in 6-cm plates or 6-well plates were mock infected or infected with rMuV, JL, rMuV⌬V, rMuV⌬SH, or rMuV⌬SH⌬V (multiple isolates) at an MOI of 0.01. One ml (6-cm plate) or 100 l (6-well plate) of supernatant was collected at 1, 2, 3, 4, 5, and 6 dpi, supplemented with 1% BSA, and stored at Ϫ80°C. Virus titers were determined by plaque assay in triplicate using Vero cells in 6-well plates. After 1 to 2 h of incubation with the viruses, the growth medium was changed to DMEM with 2% FBS, 1% P/S, and 1% lowmelting-point agarose. Four to 7 dpi, the Vero cells were stained with Giemsa stain and plaques were counted.
Immunization of mice. BALB/c mice (female, 6 to 8 weeks old) were purchased from Charles River Laboratories (Frederick, MD). Mice were immunized with 1 ϫ 10 6 PFU of rMuV, JL, rMuV⌬V, rMuV⌬SH, or rMuV⌬SH⌬V in a volume of 100 l for intranasal (i.n.) vaccination. For intramuscular (i.m.) vaccination, mice were injected with 25 l of inoculum into each side of the caudal thigh bilaterally (10 6 PFU). i.n.-or i.m.-vaccinated mice were boosted with the same amount of virus inocula as the primary vaccination on the 21st or 22nd day after primary vaccination. Blood samples were obtained from mock or recombinant MuVvaccinated mice through tail vein puncture. At the termination of each experiment, mice were euthanized with 500 l of Avertin (2,2,2-tribromoethanol) (Sigma-Aldrich) followed by cervical dislocation. Spleens were removed from the mice for splenocyte isolation and in vitro analysis. All mouse immunizations and studies with mumps viruses were performed in enhanced biosafety level 2 facilities with HEPA-filtered isolators and were conducted by following protocols reviewed and approved by the Institutional Animal Care and Use Committee of the University of Georgia.
The ELISPOT assay. Splenocytes were isolated from mouse spleens at the time of euthanasia. Spleens were ground, filtered through cell strainers (BD Falcon), and washed once with 50 ml of Hanks' balanced salt solution (Life Technologies) per spleen. Washed splenocytes from each spleen were treated with 3 ml of Gey's solution (ammonium chloride, 8.29 g/liter; potassium bicarbonate, 1 g/liter) for 5 min at room temperature (RT) to lyse red blood cells. The residual splenocytes were washed once with 50 ml Hanks balanced salt solution (HBSS) per spleen and resuspended in 10 ml complete tumor medium (CTM) containing 0.75 g/liter D-glucose (Sigma), 7.5 ml/liter essential amino acids (50ϫ) (Invitrogen), 14 ml/liter nonessential amino acids (100ϫ) (Invitrogen), 10 ml/liter sodium pyruvate (100ϫ) (Gibco), 10 ml/liter L-glutamine (100ϫ) (Gibco), 0.85 g/liter sodium bicarbonate (Sigma), 1% gentamicin-penicillin G-streptomycin sulfate (Sigma), and 3.4 l/liter 2-mercaptoethanol (Fisher) in minimum essential medium, Spinner modification (S-MEM; Sigma). Splenocytes were counted and reconstituted to a concentration of 3 ϫ 10 6 cells/ml and 1.5 ϫ 10 6 cells/ml in CTM. One hundred l of splenocytes was plated onto prepared enzyme-linked immunosorbent spot (ELISPOT) plates (MultiScreen-IP without underdrain; 0.45 m, white, sterile; Millipore). The ELISPOT plates were precoated with anti-mouse IFN-␥ (AN-18; MABTECH) overnight, washed with sterile PBS five times, and incubated with CTM for 1 h at RT. One hundred l of CTM containing either mock-infected or MuV-infected Vero cell lysates at 50 g/ml was overlaid onto splenocytes as a stimulant. Vero cell lysates were prepared by rounds of sonication and several freeze-thaw cycles to inactivate any infectious viral particles. The mixture of splenocytes and viral antigens was incubated for 40 to 48 h at 37°C with 5% CO 2 . The plates were washed after incubation, blotted with biotinylated anti-mouse IFN-␥ antibody (MAb R4-6A2; MABTECH) and streptavidin-alkaline phosphatase (MABTECH), and developed in 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium (KPL).
ELISA. Enzyme-linked immunosorbent assay (ELISA) was performed as previously described (40) . Briefly, immulon 2 HB 96-well microtiter plates (ThermoLab Systems) were coated with MuV proteins at 2 g/ml and incubated at 4°C overnight. Plates were then washed with KPL wash solution (KPL, Inc.), and each well was blocked with 200 l KPL wash solution with 5% nonfat dry milk and 0.5% BSA (Blotto) for 1 h at RT. Serum samples were inactivated by heating at 56°C for 0.5 h and were serially diluted 2-fold or 4-fold in Blotto. One hundred l of diluted serum samples was transferred to the coated plate and incubated for 1 h at RT. To detect anti-MuV specific antibodies, alkaline phosphatase (AP)-labeled, goat anti-mouse IgG (KPL, Inc.) was diluted in Blotto according to the manufacturer's instructions, added to each well, and incubated for 1 h at RT. Plates were washed and developed by adding 100 l pNPP phosphatase substrate (KPL, Inc.) per well. Optical density (OD) was measured at 405 nm on a Bio-Tek Powerwave XS plate reader.
Luciferase activity-based neutralization assay. Serum samples were serially diluted 2-fold starting from 1:10 or 1:40 up to 1:20,480. Recombinant virus expressing a Renilla luciferase protein (rMuV-Luc) was diluted to 2,000 PFU/ml in 1% BSA-DMEM. One portion of serum (40 l) was mixed with an equal volume of rMuV-Luc virus (80 PFU/40 l) into each well of a 96-well plate and incubated at 37°C with 5% CO 2 . Each 96-well plate contained five serum samples and one standard in duplicate. After 1 h of incubation, trypsinized Vero cells in 4% FBS, 2% P/S in DMEM were added to each well of the 96-well plates. At 48 to 72 h postinfection, infected Vero cells were lysed and analyzed for total luciferase activity per well using the Renilla Luciferase assay system (Promega) and a Veritas microplate luminometer (Promega). The neutralizing titer was calculated as the highest dilution level with luciferase readings exceeding that produced by 40 PFU of rMuV-Luc virus in standard control wells.
Statistics. P values were calculated using Student's t test (two-tailed, type 2). Correlations of titers determined by luciferase activity-based neutralization assay to that determined by plaque reduction neutralization assay were calculated by R 2 . Serum samples were collected at 14 days postboost (dpb). As expected, JL generated higher neutralizing antibody titers against JL than MuV, and MuV generated higher anti-MuV titers than JL, regardless of the route of immunization (Fig. 1 ). This result is consistent with a previous report that sera from JL-vaccinated humans had higher anti-JL neutralizing titers than anti-MuV neutralizing titers (41) . Previous studies have shown that rMuV⌬V (lacking V protein expression) or rMuV⌬SH (lacking SH protein expression) are attenuated in a neurovirulency potency test in rat brains (21, 36) , suggesting these viruses are good candidates for vaccine development. To investigate the immunogenicity and vaccine potential of rMuV⌬V and rMuV⌬SH in mice, BALB/c mice were mock vaccinated (PBS) or vaccinated with rMuV, JL, rMuV⌬SH, or rMuV⌬V and boosted at 22 days postprimary vaccination through i.m. injection with the same virus and dose as the primary vaccination. We chose the i.m. route because the trivalent MMR vaccine is usually administered by intramuscular (i.m.) or deep subcutaneous injection (42), but mostly via i.m. administration. Serum samples were collected at 14 dpb. The total IgG antibody titer against MuV was measured by ELISA using plates coated with purified MuV (Fig. 2) . We found that all groups generated robust anti-MuV antibody responses.
RESULTS

Immunogenicity of recombinant mumps viruses lacking either
Mumps virus is a human respiratory virus transmitted via respiratory secretions such as saliva and nose and throat discharge (6) . i.n. vaccination induces both local immunity in the respiratory tract and systemic immunity. Mucosal immunity provides direct and rapid protection against virus challenge. To examine the immunogenicity of rMuV⌬V and rMuV⌬SH compared to that of rMuV and JL, BALB/c mice were mock vaccinated (PBS) or vaccinated with rMuV, JL, rMuV⌬SH, or rMuV⌬V intranasally and boosted at 22 days postprimary vaccination with the same virus type and dose as the primary i.n. vaccination. Serum samples were collected at 14 dpb. Total IgG antibody titers against MuV were measured by ELISA (Fig. 3) . All groups generated robust anti-MuV antibody responses.
Rescue of recombinant viruses lacking both V and SH proteins. To further enhance the safety of vaccine candidates, we constructed a recombinant virus lacking expression of both the V and SH proteins. The genome length of the newly synthesized cDNA (pMuV⌬SH⌬V) complied with the rule of six for Paramyxovirus 6 PFU. Serum samples were collected at 14 dpb, and total antibody titers in these samples were measured by ELISA coated with MuV viral proteins. (43) . Infectious recombinant viruses (rMuV⌬SH⌬V) were rescued from BSRT-7 cells transfected with pMuV⌬SH⌬V and helper plasmids as described before (21) . To confirm rescue of the virus, viral RNA was extracted from cell culture medium containing rescued viruses (Fig. 4B) . The SH gene and the V/P gene region were amplified using reverse transcription-PCR and sequenced. As shown in Fig.  4 , the SH ORF truncation as well as the V deletion was confirmed (Fig. 4C and D) .
To confirm that genomic changes in rMuV⌬SH⌬V abolish V and SH expression, Vero cells were mock infected or infected with rMuV or rescued rMuV⌬SH⌬V (PX64-67 strain). Expression levels of MuV NP, P, V, and SH proteins were examined using Western blotting. While NP and P were detected in both rMuV-and rMuV⌬SH⌬V-infected cells, expression of V or SH protein was only detected in rMuV-infected Vero cells (Fig. 4E) .
Analysis of rMuV⌬SH⌬V in tissue culture cells. To select an rMuV⌬SH⌬V virus that replicates well for vaccine production purposes, the replication capability of rMuV⌬SH⌬V viruses from 6 in- dividual rescues, designated PX64-N, were compared by multicycle growth kinetics in Vero cells. While most rMuV⌬SH⌬V viruses reached the peak virus titer within the first 72 h postinfection (hpi), PX64-4 grew slower than the others and peaked at 96 hpi. Three strains (PX64-4, PX64-61, and PX64-67) grew to a titer close to 10 7 PFU/ml, and the other three strains (PX64-1, PX64-2, and PX64-81) had titers ranging from 5.5 ϫ 10 5 to 6 ϫ 10 5 , 1 to 1.5 logs lower than the former strains (Fig. 5A ). PX64-67 had a growth pattern similar to that of full-length rMuV (virus titer peaking during first 48 hpi) and the highest virus titer among rMuV⌬SH⌬V viruses. Therefore, it was chosen and designated rMuV⌬SH⌬V for the following studies. Previously, when we obtained rMuV⌬V, mutations in regions other than the designed V/P editing site always arose. The entire genome of the rescued rMuV⌬SH⌬V viruses were sequenced to determine whether genome-wide mutations occurred during virus rescue. PX64-67 contained an additional single-nucleotide change (C-T) in genomic position 1913 (termed 1913 C-T) (NP gene end) and 7894 T-A silent (HN ORF) mutations compared to rMuV. To compare the growth of rMuV⌬SH⌬V to rMuV and parental viruses (rMuV⌬SH and rMuV⌬V), Vero cells were infected with rMuV, rMuV⌬SH, rMuV⌬V, and rMuV⌬SH⌬V at an MOI of 0.01. While rMuV⌬SH showed growth kinetics comparable to those of rMuV, consistent with previously published data (21), rMuV⌬V and rMuV⌬SH⌬V were about a half log lower in virus titer. The virus titer of rMuV⌬SH⌬V decreased after 48 hpi, remaining about a half log lower than that of rMuV⌬V and one log lower than that of rMuV or rMuV⌬SH (Fig. 5B) .
Intracellular viral protein expression of rMuV⌬SH⌬V was compared to that of rMuV. NP, P, and V protein expression levels were examined (Fig. 5C ). Comparable NP and P protein levels were detected in Vero cells infected with rMuV or rMuV⌬SH⌬V. However, secretion of infectious viral particles of rMuV⌬SH⌬V-infected Vero cells was less than that of rMuV-infected Vero cells at all time points postinfection (Fig. 5C ). At 48 hpi, a more intense P protein band was observed in rMuV⌬SH⌬V-infected cells than in rMuV-infected cells, consistent with a previous report of higher P expression at early time points in rMuV⌬V viruses, a likely result of increased P transcription from the V/P gene due to deletion of the V mRNA transcript (36) . Expression of the V protein was only detected in rMuV-infected cells.
Maintenance of V and SH protein deletion in rMuV⌬SH⌬V through 10 passages in Vero cells. To examine the stability of rMuV⌬SH⌬V, it was passed in Vero cells continuously for 10 passages at a low MOI. At passage 10 (rMuV⌬SH⌬V P10), the culture medium from infected Vero cells was used for viral RNA extraction, followed by whole-genome sequencing to determine the consensus genome sequence. Sequencing results revealed 3 additional mutations: 1 silent mutation in the HN ORF, an R154K mutation in P, and an N2063H mutation in L. Interestingly, the G-A nucleotide mutation at position 2445 in the P ORF is the first nucleotide of the 6-guanine editing site (GGGGGG) of the V/P gene, which has been altered to GAGGAGGG in rMuV⌬SH⌬V and rMuV⌬V viruses (36) . Importantly, none of these mutations affected deletion of V or SH.
Furthermore, 10 single plaques (designated SP-1 to SP-10) were obtained from rMuV⌬SH⌬V P10, and the V/P and SH gene regions were sequenced (Table 1 ). The V protein and the SH ORF deletion were maintained in all 10 progeny strains from passage 10, including the 1913 C-T mutation in the NP gene end region. While 9 out of 10 strains contained the 2445 G-A mutation in the V/P gene editing site, 1 strain lost/failed to retain this mutation. To confirm that the 2445 G-A mutation had no effect on the V protein deletion, expression of the V protein in SP-1-to SP-10-infected Vero cells was examined by Western blotting (Fig. 6) . No expression of V was detected, indicating that the mutation had no effect on V protein deletion.
Intramuscular immunization of BALB/c mice with rMuV⌬ SH⌬V generated an antibody response against MuV. BALB/c mice were i.m. vaccinated with rMuV, JL, rMuV⌬SH, rMuV⌬V, or rMuV⌬SH⌬V as described above. Serum samples were collected as described previously. Serum IgG antibody titers against MuV were measured using ELISA with plates coated with MuV viral proteins (lysed virions). Neutralizing antibody titers against MuV were measured by an rMuV-Luc-based neutralization assay as described in Materials and Methods (linear correlation of rMuVLuc-based neutralization assay to traditional plaque reduction neutralization assay was confirmed by an R 2 value of 0.9317 using ferret serum samples [data not shown]). Similar approaches have been used for adenovirus, measles virus, and respiratory syncytial virus (RSV) to substitute for the traditional plaque reduction neutralization test (PRNT) (44) (45) (46) (47) . We used rMuV-Luc, which was constructed based on the genetic background of MuV, as the targeting virus to compare the potentials of humoral responses induced by the vaccine candidates as well as the JL strain in mice to protect against the circulating mumps virus in the United States. No significant differences were detected among the groups for total antibody titers (Fig. 7A) . However, the neutralizing antibody titers of serum samples showed some differences. The average neutralizing titer of JL-inoculated mice was significantly lower than that of rMuV-infected mice, which had the highest neutralizing titer. Mice inoculated with rMuV⌬SH, rMuV⌬V, or rMuV⌬SH⌬V had similar average titers (Fig. 7B) .
Intranasal immunization of BALB/c mice with rMuV⌬ SH⌬V generated an antibody response against MuV. BALB/c mice were i.n. inoculated with rMuV, JL, rMuV⌬SH, rMuV⌬V, or rMuV⌬SH⌬V at 10 6 PFU, and serum samples were collected for measurement of both total antibody titer and neutralizing titer against MuV. rMuV⌬SH-inoculated mice developed the highest total antibody titer, and the rMuV group had a higher titer than the JL group. No significant differences were detected among the JL group, rMuV⌬V group, and rMuV⌬SH⌬V groups (Fig. 8A) . The rMuV group had the highest neutralizing titer, the JL group had the lowest neutralizing titer, and the other three groups (rMuV⌬SH, rMuV⌬V, and rMuV⌬SH⌬V) ranked between them (Fig. 8B) . Although i.n.-immunized mice exhibited neutralizing antibody titer patterns like those observed in the i.m. groups, statistically significant differences were found between the rMuV and JL groups (P ϭ 0.001), JL and rMuV⌬SH groups (P ϭ 0.001), JL and rMuV⌬SH⌬V groups (P ϭ 0.038), and rMuV⌬V and rMuV⌬SH groups (P ϭ 0.034).
Adaptive T cell responses were induced in mice vaccinated with rMuV⌬SH⌬V. To investigate the cellular immune responses induced by rMuV⌬SH⌬V, i.m.-or i.n.-inoculated mice were euthanized at 28 dpb and splenocytes were isolated for ELISPOT assay. In i.m.-inoculated mice, the JL group had the highest T cell response levels and rMuV⌬SH⌬V had the lowest T cell response levels, with no distinguishable differences among the rMuV, rMuV⌬SH, and rMuV⌬V groups (Fig. 9A ). Differences were significant between JL and rMuV⌬SH, JL and rMuV⌬SH⌬V, rMuV⌬SH and rMuV⌬SH⌬V, and rMuV⌬V and rMuV⌬SH⌬V. In i.n.-inoculated mouse groups, rMuV-and rMuV⌬V-immu- nized mice had the lowest responding cell counts (Fig. 9B) . Significant differences were observed between JL and rMuV⌬V, rMuV and rMuV⌬SH, rMuV and rMuV⌬SH⌬V, rMuV⌬SH and rMuV⌬V, and rMuV⌬V and rMuV⌬SH⌬V groups.
DISCUSSION
The JL vaccine is one of the most successful vaccines developed during the third quarter of the last century. It was produced by the propagation of mumps virus in embryonated hen's eggs that resulted in attenuation (48) (49) (50) (51) . Introduction of the in vitro tissue/ cell culture technique into vaccinology facilitated the development and production of the majority of currently licensed liveattenuated vaccines in the United States against viral infections (52) (53) (54) (55) (56) . For mumps vaccine candidates, JL is the great success, but unfortunately there were many failures. Different passages of attenuated viruses were tested in animal models or in field trials in order to select a vaccine seed with the most reduced virulence and greatest immunogenicity (1) . Selected vaccine candidates need to be biologically characterized in order to be distinguished from virulent strains. There are currently no standardized attenuation markers for mumps vaccines, partially due to the semirational and semiempirical nature of the traditional attenuation method (1, (57) (58) (59) (60) . The rate of aseptic meningitis following vaccination with JL (estimated one case per 1.8 million doses) is below background levels (61) . However, other live attenuated mumps virus vaccines have had much higher incidences of vaccine-associated meningitis. The Urabe vaccine, which was widely distributed in Japan, Europe, and Canada, is estimated to cause one case of meningitis in every 1,000 to 11,000 doses distributed in the United Kingdom and one case of meningitis in every 62,000 doses distributed in Canada. The Urabe vaccine has been withdrawn due to safety concerns.
In this study, based on the establishment of reverse genetic technology of negative-sensed, nonsegmented RNA viruses (62-66), we examined the possibility of generating a new mumps vaccine candidate through deletion of V and SH protein expression from a clinical isolate from a 2006 Iowa mumps epidemic (MuV, genotype G). Deletion of either of the proteins has been previously reported to reduce mumps neurotoxicity in IC-infected rats. Importantly, since deletion of the V protein alone (from the MuV strain) is sufficient to reduce the neurovirulence potential of the recombinant virus to a level comparable to that of the JL vaccine (21, 36) , the lack of V protein expression can be used as an attenuation marker for our vaccine candidates.
Attenuation based on targeted genetic modification has several advantages. The most commonly used mumps vaccine, JL, is a mixture of at least two well-distinguished components (67) (68) (69) . Surveillance of the compositional balance between the two components during vaccine preparation and propagation has been proposed (68) . However, cDNA-derived recombinant viruses have defined consensus sequences and higher homogeneity. They are plaque purified, whole genome sequenced, and passed in Vero cells only for the purpose of amplification. Vaccine candidates can be continuously rescued from the cDNA plasmids with a defined consensus sequence and clear genetic markers for attenuation. All processes are cell culture based, bypassing the necessity of highquality pathogen-free chickens, chicken eggs, or any other animals used for in vivo adaption (70) (71) (72) . Omission of the serial passages saves time for vaccine development and avoids potential adaption-induced antigen shifts of the vaccine strains; therefore, it retains the maximum amount of immunogenic epitopes.
Mumps viruses are classified into 12 genotypes based on genetic variability of the SH gene (73, 74) . Different subtypes of mumps viruses exhibit distinguished geographic distribution worldwide. Although the driving force of such distribution remains unclear, emergence of new subclusters of circulating mumps viruses within a genotype (75, 76) indicates evolution of wild-type mumps viruses under various selection forces. Failure to detect genotype A wild-type mumps viruses in countries/regions immunized with genotype A vaccine in recent studies may be due to a vaccine-based selection pressure. This pressure may select for genotypes with increased virulence and heterogeneity compared to current vaccines (77) (78) (79) (80) (81) (82) . Decreased neutralization capabilities against heterogenotypes among subtypes of mumps viruses (83) (84) (85) (86) and lack of cross protection between different subtypes (genotype D against genotype A) in human natural infection have been reported (87) . It would be ideal to use a genotype-matched vaccine candidate (genotype G), which elicits more specific immune responses that effectively protect against the circulating mumps viruses in the United States (genotype G) (11, 13, 78, 79) .
Although additional mutations occurred during rMuV⌬SH⌬V virus rescue and during passages of rMuV⌬SH⌬V in Vero cells, no regaining of the V protein or the SH protein was observed in any rMuV⌬SH⌬V viruses analyzed, indicating that rMuV⌬SH⌬V is stable in tissue culture cells. Interestingly, besides two silent mutations in the HN and L ORFs, rMuV⌬SH⌬V (PX64-67) possessed one nucleotide change (C-T) in genomic position 1913 in the V/P GS region, which has been previously seen in the course of rMuV⌬V virus rescue (36) . This mutation is believed to be important in regulating the transcription/translation level of P protein, emphasizing the significance of a proper ratio between NP and P protein during virus growth.
One challenge of developing a new mumps vaccine is the lack of correlation between protection and immune responses. While a neutralization titer is thought to be essential in protection against mumps infection (79) , investigations of serum samples of patients versus nonpatients during recent mumps outbreaks revealed no defined cutoff neutralizing antibody titer against mumps virus, indicating a potential role for cellular immunity in effective protection against mumps challenge (41, 86) . In this study, the investigation of immunogenicity of rMuV⌬SH⌬V in i.n.-and i.m.-vaccinated mice showed that rMuV⌬SH⌬V was able to induce a neutralizing titer comparable to those induced by rMuV⌬SH and rMuV⌬V and a higher titer than that induced by JL vaccine. Furthermore, rMuV⌬SH⌬V vaccination also stimulated T cell responses in mice, although the role of cell-mediated immunity in mumps disease protection remains to be demonstrated. We also observed that rMuV⌬SH induced slightly higher total antibody titers than those induced by rMuV, and rMuV⌬SH⌬V induced higher antibody titers than those induced by rMuV⌬V, suggesting that deletion of SH leads to better antigen presentation. Similar results have been reported for a closely related virus, parainfluenza virus 5 (PIV5), in which PIV5 lacking SH is more immunogenic than PIV5 (88) . The mouse models have been widely used to test vaccine efficacy for various human viruses (89) (90) (91) (92) . However, it is not a good model for mumps virus infection. The efficacy of rMuV⌬SH⌬V in nonhuman primates, which is a good model for mumps virus infection (40) , should be examined before testing this candidate in humans. In summary, rMuV⌬SH⌬V was able to elicit both antibody and cellular responses against MuV in i.n.-and i.m.-vaccinated mice, providing a safe and immunogenic mumps vaccine candidate.
